NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

CTOR

Citius Oncology Inc

Jul 08 • 04:00PM ET

4.26

Dollar change -0.45
Percentage change -9.55	%

Healthcare • Drug Manufacturers - Specialty & Generic • USA • NASD

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-0.19	Insider Own	95.08%	Shs Outstand	71.55M	Perf Week	-2.07%
Market Cap	304.81M	Forward P/E	85.20	EPS next Y	0.05	Insider Trans	0.00%	Shs Float	3.52M	Perf Month	339.18%
Enterprise Value	308.61M	PEG	-	EPS next Q	-0.15	Inst Own	0.15%	Short Float	3.23%	Perf Quarter	517.30%
Income	-20.86M	P/S	-	EPS this Y	-54.84%	Inst Trans	-36.96%	Short Ratio	0.10	Perf Half Y	257.98%
Sales	0.00M	P/B	8.55	EPS next Y	110.42%	ROA	-	Short Interest	0.11M	Perf YTD	270.43%
Book/sh	0.50	P/C	-	EPS next 5Y	-	ROE	-	52W High	49.00 -91.31%	Perf Year	-62.47%
Cash/sh	0.00	P/FCF	-	EPS past 3/5Y	-537.43% -	ROIC	-52.88%	52W Low	0.55 673.70%	Perf 3Y	-
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	18.68% 27.06%	Perf 5Y	-
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	-197.09%	Oper. Margin	-	ATR (14)	0.65	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	0.05	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	68.68	Recom	3.00
Dividend Gr. 3/5Y	- -	Current Ratio	0.36	EPS Q/Q	-	SMA20	44.82%	Beta	3.10	Target Price	3.00
Payout	-	Debt/Eq	0.11	Sales Q/Q	-	SMA50	149.27%	Rel Volume	0.23	Prev Close	4.71
Employees	-	LT Debt/Eq	0.11	Earnings	May 14 AMC	SMA200	244.47%	Avg Volume	1.14M	Price	4.26
IPO	Dec 08, 2022	Option/Short	No / Yes	EPS/Sales Surpr.	- -100.00%	Trades		Volume	263,518	Change	-9.55%

Date	Action	Analyst	Rating Change	Price Target Change
Nov-27-24	Initiated	Maxim Group	Buy	$3

Jun-26-25 11:44AM	The $900 Billion Question: Who Will Deliver the Next Cancer Breakthrough? (PR Newswire) +26.81%
Jun-17-25 08:08AM	Citius Oncology Anticipates Commercial Launch of LYMPHIR in 2025 (PR Newswire)
Jun-12-25 09:00AM	After Major Oncology Conference, All Eyes Turn to Industry Innovation (PR Newswire)
Jun-09-25 08:37AM	Citius Oncology Enters into Distribution Services Agreement with Cardinal Health (PR Newswire) +17.13%
May-14-25 04:30PM	Citius Oncology, Inc. Reports Fiscal Second Quarter 2025 Financial Results and Provides Business Update (PR Newswire)
04:30PM	Loading…
Feb-14-25 04:30PM	Citius Oncology, Inc. Reports Fiscal First Quarter 2025 Financial Results and Provides Business Update (PR Newswire) -5.60%
Feb-06-25 08:55AM	Citius Pharmaceuticals and Citius Oncology Announce Unique Permanent J-Code Issued for LYMPHIR by Centers for Medicare and Medicaid Services (PR Newswire) -5.56%
Jan-07-25 08:08AM	Citius Pharmaceuticals and Citius Oncology Highlight LYMPHIR Commercial Launch Planned for the First Half of 2025 (PR Newswire) -11.69%
07:57AM	Citius Oncology to explore strategic alternatives (TipRanks)
Jan-06-25 07:50AM	Citius Oncology Engages Jefferies as Exclusive Financial Advisor to Explore Strategic Alternatives (PR Newswire) +18.46%
Dec-31-24 07:10AM	Citius Pharmaceuticals upgraded to Buy from Hold at D. Boral Capital (TipRanks)
Dec-27-24 05:00PM	Citius Pharmaceuticals, Inc. Reports Fiscal Full Year 2024 Financial Results and Provides Business Update (PR Newswire) +8.33% +7.69%
05:00PM	Citius Oncology, Inc. Reports Fiscal Full Year 2024 Financial Results and Provides Business Update (PR Newswire)
Nov-11-24 08:45AM	Citius Pharmaceuticals, Inc. and Citius Oncology, Inc. Announce Promising Preliminary Results of an Investigator-Initiated Phase I Clinical Trial of Pembrolizumab (KEYTRUDA) and LYMPHIR in Cancer Patients with Recurrent Solid Tumors (PR Newswire) +6.30%
Sep-05-24 04:30PM	Citius Pharmaceuticals to Participate in the H.C. Wainwright 26th Annual Global Investment Conference (PR Newswire) +8.38% -5.60%
08:30AM	Loading…
08:30AM	Citius Pharmaceuticals, Inc. and Citius Oncology, Inc. Announce LYMPHIR (Denileukin Diftitox-cxdl) Added to National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology (PR Newswire)

Citius Oncology, Inc. is a pharmaceutical company, which engages in developing and commercializing targeted oncology therapies. Its lead product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein, for the treatment of patients with persistent or recurrent CTCL, a rare form of non-Hodgkin lymphoma. The company was founded on March 1, 2021 and is headquartered in Cranford, NJ.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

CTOR

Citius Oncology Inc

Upgrade your FINVIZ experience